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Moderation of antipsychotic-induced weight gain by
energy balance gene variants in the RUPP autism
network risperidone studies
EL Nurmi1, SL Spilman1, F Whelan1, LL Scahill2, MG Aman3, CJ McDougle4, LE Arnold5, B Handen6, C Johnson6, DG Sukhodolsky2,
DJ Posey7, L Lecavalier3, KA Stigler7, L Ritz8, E Tierney9, B Vitiello10, JT McCracken1 and the Research Units on Pediatric
Psychopharmacology Autism Network
Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that
varies widely across individuals. We queried common variation in key energy balance genes (FTO,MC4R, LEP, CNR1, FAAH) for
their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology
Autism Network trials (N¼ 225) of risperidone for treatment of irritability in children/adolescents aged 4–17 years with autism
spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P¼ 1.0 10 6), CNR1 (P¼ 9.6 10 5) and the
leptin (LEP) promoter (P¼ 1.4 10 4) conferred robust-independent risks for weight gain. A model combining these three
variants was highly significant (P¼ 1.3 10 9) with a 0.85 effect size between lowest and highest risk groups. All results
survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for
association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas
body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data
suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychotic-
associated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust
enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights
compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event.
Translational Psychiatry (2013) 3, e274; doi:10.1038/tp.2013.26; published online 25 June 2013
Introduction
Antipsychotic-induced weight gain (AIWG) is a common and
limiting side effect of antipsychotic treatment, especially of
the widely prescribed second-generation antipsychotics
(SGA).1 Intersubject variability in this adverse effect may be
explained in part by individual genetic differences; heritability
may be as high as 80% based on comparisons of clozapine-
treated monozygotic twins and sex-matched siblings.2
Although AIWG is thought to be multifactorial, most of the
extant research has focused on monoaminergic systems
given their role in direct drug effects and their involvement in
appetite, satiety, metabolism and activity.3–5 Relatively
modest variance in AIWG has been explained by association
of common variants in these systems, suggesting that
additional moderators in other pathways are likely, rare
variants may be involved, or that confounding environmental
effects exist. Further support for the existence of novel
candidates is provided by pharmacogenomic analyses of the
CATIE study of SGA-treated adults with schizophrenia, in
which weight gain and metabolic effects were variably
associated with several genes not considered to be ‘drug
targets’.6
Energy balance pathways. Energy intake and expenditure
are regulated by the central nervous system, liver, gastro-
intestinal tract and adipose tissue to maintain energy
balance. In the central nervous system, melanocortin 4
receptor (MC4R) signaling has a key role in regulating
feeding behavior in the hypothalamus. The central melano-
cortin system regulates hepatic and adipocyte lipid metabo-
lism.7,8 Mutations in the MC4R gene are the most common
monogenic cause of severe obesity in humans.9 In addition,
the mesolimbic dopamine pathway modulates reinforcing
and motivational effects of food. The FTO (fat mass and
obesity-associated) gene, highly expressed in the hypotha-
lamus,10 was identified by a genome-wide association study
for its strong association with body mass index (BMI)11 and
this link was subsequently replicated independently and in a
meta-analysis.12 FTO expression appears to be sensitive to
fasting and feeding.13,14
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Leptin (LEP) promotes satiety and leanness through
multiple inputs to the energy balance circuit. LEP is secreted
by adipose tissue in proportion to fat stores, and activates
hypothalamic MC4R signaling to inhibit feeding and increase
energy expenditure.15 Recently, effects on reinforcement and
motivation via mesolimbic dopamine signaling have been
demonstrated.16,17 Peripherally, LEP regulates lipid and
glucose metabolism through the autonomic nervous sys-
tem.18,19 Obesity-producing spontaneous null mutations in
LEP and the LEP receptor (LEPR ) in mice prompted its
discovery.20 LEP antagonism in rats increases feeding,
promotes weight gain and reduces activity.21 Although humans
genetically lacking LEP are morbidly obese,22 mixed associa-
tion results and a negative meta-analysis23 suggest that LEP
does not have a major role in common variability in body weight.
Endocannabinoids trigger feeding behavior and weight gain
through stimulation of widely expressed cannabinoid 1 (CB1)
receptors (CNR1).24 In the brain, the endocannabinoid
system regulates both mesolimbic reinforcement25,26 and
hypothalamic feeding pathways. CB1 signaling promotes
feeding through positive effects on orexins27 and inhibition of
MC4R,28 and is in turn stimulated by ghrelin29 and inhibited by
LEP30 and cholecystokinin.31 Endocannabinoid signaling in
the liver and adipose tissue regulates lipid metabolism,
adipogenesis and adiponectin release.32 CB1 receptor agon-
ism increases and antagonism reduces food intake and body
weight in both humans and animal models.33,34 Mice lacking
CB1 expression exhibit hypophagia and leanness at baseline,
and are resistant to high-fat diet-induced metabolic changes,
behaviors and obesity.35 Polymorphisms in CNR1 and the
gene encoding the catabolic enzyme (fatty acid amide
hydrolase (FAAH )) have been associated with obesity
phenotypes; however, data are mixed.36,37 In the RIO-North
America trial, 2-year treatment with a CB1 antagonist, rimona-
bant, in combination with a healthy diet, resulted in modest
reductions in weight, waist circumference and cardiometa-
bolic risk factors.38 The drug did not reach the US market,
however, due to psychiatric side effect concerns.
Energy balance candidate genes in AIWG. A few reports
have begun to investigate whether variants in metabolic and
appetite gene loci, such as LEP, may moderate AIWG.5
These studies were prompted by observed increases in
plasma LEP levels during SGA treatment.39 Common LEP
gene variants have reportedly moderated AIWG in some but
not all studies,5 including one pediatric sample.40 Variants
mapping adjacent to the MC4R gene have recently been
demonstrated to predict AIWG in multiple independent
samples.41,42 Given the role of the endocannabinoid system
in energy balance and observed CNR1 upregulation in
response to antipsychotic treatment,43 two recent pharma-
cogenomic studies have supported a contribution of endo-
cannabinoid involvement. One report demonstrated
moderation of AIWG in schizophrenia by a functional
polymorphism in CNR1.44 A second study demonstrated an
association between AIWG and a nonsynonymous variant in
the gene encoding the degradative enzyme, FAAH.45
The established role of the melanocortin, LEP and
endocannabinoid systems in energy balance and the asso-
ciation of gene variants with human obesity strongly suggest
these systems as possible moderators of AIWG, perhaps as
an alternative pathway to direct drug action at monoaminergic
and other targets. Relatively few studies have examined the
effects of common gene variants in these systems, and to our
knowledge, none have attempted a systematic, combined
examination of these loci in relation to AIWG. In addition, most
reports have not queried each locus thoroughly, relying
instead on rather few frequently studied polymorphisms.
Importantly, extant genetic studies of variants in the energy
balance system have been mainly limited to adults, despite
common use of SGAs in children. Reports suggest that
pediatric populations are at equal or greater risk of AIWG.46–49
In the NIMH Research Units on Pediatric Psychopharmacol-
ogy (RUPP) trials, weight gain above that predicted with
normal development was evident after just 8 weeks and
continued after 6 months of risperidone exposure.50 Other
longitudinal studies show persistent effects at 1 year.48
Studying AIWG in children has several scientific advantages,
such as fewer concomitant and potentially confounding
medical comorbidities and medications, and lower rates of
institutionalization, smoking and substance use/abuse.
Further, increased weight in children confers serious health
risks, social impairment, challenges to self-esteem and risk for
adult obesity. In light of the potential importance of energy
balance genes as moderators of AIWG and sparse investiga-
tion in pediatric samples, we examined the association of
genetic variants in these systems with weight gain in our
combined sample from two clinical trials of children and
adolescents receiving risperidone treatment for severe irrit-
ability associated with autism spectrum disorders (ASDs).51,52
Materials and methods
The research was conducted by the RUPP Autism Network
under two protocols approved by individual site Institutional
Review Boards and by a National Institute of Mental Health
Data Safety Monitoring Board. Written informed consent (and
assent from the child, when capable) was obtained from a
parent or guardian before enrollment. Youth (ages 4–17
years) meeting DSM-IV criteria for ASD (autism, Asperger’s
disorder, pervasive developmental disorder not otherwise
specified) accompanied by severe irritability (aggression,
tantrums, and/or self-injurious behaviors) defined by a score
ofX18 on the Aberrant Behavior Checklist Irritability subscale
were treated for 8 weeks with risperidone or placebo as part of
two controlled trials, RUPP51 and RUPP-PI (RUPP-Psycho-
social Intervention).51,52 Only 10% of subjects had previously
received (ineffective) antipsychotic treatment; subjects with
prior adequate trials of risperidone were excluded. In the
RUPP sample, subjects included both those randomized first
to risperidone in the 8-week acute phase and non-responders
to 8 weeks of initial placebo treatment who were then openly
treated with risperidone according to an identical titration and
assessment protocol.51 In the RUPP-PI study, all subjects
received risperidone, titrated as in the RUPP study, with or
without parent behavior management for up to 24 weeks.52 Of
the 225 total outpatients enrolled from the two trials, weekly
measures of weight, height, BMI and genotype data were
available for a combined 184 subjects from their initial 8-week
acute exposure to risperidone. Plasma drug and metabolite
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levels were analyzed for the RUPP sample according to
previously published protocols.53
The RUPP and RUPP-PI groups were compared using the
appropriate w2, analysis of variance or t-test to ensure
comparable samples (Table 1). Baseline variables that were
significantly different between the two groups were tested in
the final model and dropped if they showed no significant
effect on outcome. Weight was transformed to standardized z-
scores using anthropometric indices based on the 2000 CDC
growth charts using the CDC SAS program,54 as described in
a previous report.50 A separate repeated measures mixed
effects model was constructed for each single-nucleotide
polymorphism (SNP) with change in weight z-score from
baseline as the main outcome. Genotype, visit (as a
continuous variable) and interaction of genotype by visit were
entered as predictors, controlling for baseline weight z-score.
Other potentially confounding covariates were entered in the
initial model such as dose, plasma drug level and ethnicity, but
were nonsignificant and therefore dropped from the final
model.
The linkage disequilibrium (LD) structure of MC4R, LEP
and CNR1 were examined using the Broad Institute Tagger
software55 to select markers (Table 2), which span each gene
and capture common variability (41%) in this genomic region,
with a mean max r240.98 for LEP and r2¼ 1 for MC4R. Our
CNR1 tag is less robust according to the latest genome build,
with a mean max r240.61 for alleles with 410% frequency
across the CNR1-coding region. Tags were chosen based on
the European Caucasian reference genome, given that our
population is 70% Caucasian and thus provides little power to
detect population-specific alleles in non-Caucasian subsets.
A well-characterized, functional variant (rs324420) in FAAH
Table 1 Characteristics of the RUPP, RUPP-PI and combined RUPP risperidone Autism samples
RUPP (n¼71) RUPP-PI (n¼110) Combined (n¼ 181) P-value
Gender (n (%) male) 56 (78.9%) 92 (83.6%) 148 (81.8%) w2¼0.66, P¼0.4177
Baseline age (months) 106.66±34.5 89.96±29.0 96.5±32.3 T¼3.51, P¼0.0006
Baseline BMI 18.2±4.9 17.7±3.1 17.9±3.92 T¼ 0.85, P¼0.40
Ethnicity (n (%)) w2¼ 14.9, P¼ 0.02
White, non-Hispanic 51 (71.8%) 74 (67.3%) 125 (69.0%)
Black, non-Hispanic 6 (8.5%) 20 (18.2%) 26 (14.4%)
Native American 0 2 (1.8%) 2 (1.1%)
Asian or Pacific Islander 7 (9.9%) 5 (5.5%) 13 (7.2%)
Hispanic 2 (2.8%) 7 (6.4%) 9 (5.0%)
Black, Hispanic 0 1 (0.9%) 1 (0.6%)
Other 5 (7.0%) 0 5 (2.8%)
Duration of treatment
Median (range) weeks 8 (6–8) 8 (1–8) 8 (1–8) w2¼ 4.08, P¼0.54
Final dose (mg) 1.84±0.63 2.09±0.59 2.00±0.62 T¼  2.66, P¼0.0084
Mean weight gain (kg) 2.84±2.05 2.57±1.51 2.68±1.74 T¼0.97, P¼0.3317
Abbreviations: BMI, body mass index; RUPP, Research Units on Pediatric Psychopharmacology; RUPP-PI, RUPP-psychosocial intervention.
Table 2 Association of genetic variants in energy balance pathways with AIWG
Gene SNP ID (rs#) Gene region Our MAF HapMap MAF P-value Prior association
FTO rs1421085 Intron 1 0.33 0.45 0.13 12
rs6499640 Intron 1 0.41 0.35 0.88 81
rs1121980 Intron 1 0.41 0.48 0.78 12,82
rs17817449a Intron 1 0.39 0.45 83
rs8050136a Intron 1 0.38 0.45 12
rs9939609a Intron 1 0.38 0.45 11,73
MC4R rs8087522 Promoter 0.36 0.36 0.06 41,84
rs11872992 Promoter 0.12 0.13 0.03 41,84
rs8093815 30 Downstream 0.32 0.33 0.07
rs489693 30 Downstream 0.39 0.34 0.03 85
LEP rs7799039 promoter 0.43 0.49 1.4104 72,86,87
rs10244329 Intron 1 0.49 0.47 9.6103 88
rs12706832 Intron 1 0.49 0.57 0.09
rs2071045 Intron 2 0.24 0.21 0.19 89
CNR1 rs806378 Variableb 0.24 0.26 1.0106 44
rs806377 Promoter 0.46 0.49 0.17
rs1049353 Synonymous 0.23 0.23 9.6105
rs806368 30UTR 0.18 0.25 0.26
FAAH rs324420 Nonsynonymous 0.25 0.21 0.19 45
Abbreviations: AIWG, antipsychotic-induced weight gain; CNR, cannabinoid receptor; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; UTR,
untranslated region.
aFTO SNPs removed from analysis due to near perfect linkage disequilibrium with rs1121980. brs806378 maps to either a promoter, 50UTR, or intronic location in
alternatively processed CNR1 transcripts.
Bolded P-values are significant after Bonferroni-correction for 19 tests.
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was included to more comprehensively evaluate the endo-
cannabinoid system. Six SNPs in FTO with genome-wide
association study support for obesity were also examined;
however, four of these were in near perfect LD, thus only one
was included in the final analyses. Genomic DNA was
extracted from whole blood using QiaAmp DNA Blood Mini
Kits (Qiagen, Valencia, CA, USA). Genotyping was performed
using the TaqMan genotyping platform (Life Technologies,
Grand Island, NY, USA) with Qiagen Type-it Fast SNP Probe
PCR Kit (Qiagen) according to manufacturer’s protocols. All
markers were in Hardy–Weinberg equilibrium, 10% of the data
set was genotyped in duplicate with perfect concordance, and
allele frequencies were consistent with those reported by the
HapMap Consortium (Table 2).56 Functional potential of
associated SNPs was explored using online databases,
including the online UCSC Genome Browser57 with ENCODE
tracks58 and the Broad Institute’s HaploReg online resource
(accessed 4 November 2012).59
A combined risk variable was constructed using the three
significant markers, in part to examine the relative indepen-
dence of each marker. Genotype at each locus was given a
score of 0 or 1, with 1 denoting the presence of at least one risk
allele. Scores were summed across the three loci and each
subject received an overall risk score ranging from 0 to 3. A
similar repeated measures mixed effects model (predicting
change in weight z-score based on risk score, visit and visit by
risk score) was applied, with baseline weight as a covariate.
Results
The two studies were roughly equivalent with respect to
demographic and baseline characteristics, final risperidone
daily dose and weight gained (Table 1). Statistical compar-
isons of the two study populations showed small clinical
differences: RUPP-1 subjects were 16.7 months older,
weighed 0.27 kg more at baseline and received an average
of 0.25 mg less total daily risperidone compared with RUPP-PI
participants. Whereas both samples were predominantly
Caucasian (B70%), there were minor ethnicity differences
across the samples. As a result, significant associations with
gene variants were repeated with ethnicity and risperidone
dose as covariates. The mean absolute weight increase for
the combined sample (Table 1) was 2.68±1.74 kg (9.8% of
baseline) with an increase in BMI of 8.3% from baseline (final
BMI¼ 19.3±3.9) following 8 weeks of risperidone exposure
(mean final dose 2±0.62 mg per day). Of note, the decrease
in Aberrant Behavior Checklist-Irritability subscale score
(primary outcome) from baseline to 8 weeks was significantly
inversely correlated with weight gain in kilograms (r¼  0.36,
Po0.0001). Drop-out rates were very low with more than 95%
completing the entire 8-week study.
Three independent gene variants were associated with
z-score weight change at a Bonferroni-corrected significance
level, one in LEP and two in CNR1 (Figure 1; Supplementary
Table 1). The T-allele of the CNR1 rs806378 polymorphism
predicted an allele dosage-dependent increase in AIWG
(P¼ 1.0 10 6, Figure 1a). The increase in age-corrected
BMI for the three genotype groups was 1.85 for TT
homozygotes, 1.57 for CT heterozygotes and 1.34 for CC
homozygotes. The G-allele of the commonly studied
(rs1049353) synonymous variant in the large, final exon of
CNR1 conferred an independent risk for weight gain (P¼ 9.6
 10 5), suggesting allelic heterogeneity at this locus.
G-allele carriers gained more weight than AA homozygotes,
with change in BMI of 1.25 for GG homozygotes, versus 1.49
for AG heterozygotes and AA homozygotes. The G-allele
of the LEP rs7799039 promoter SNP acted dominantly to
increase weight gain compared with A-allele homozygotes
(P¼ 1.4 10 4, Figure 1b). Change in BMI of GG homo-
zygotes and AG heterozygotes was 1.37 and 1.43 respectively,
compared with 1.07 in AA homozygotes. A second marker,
rs10244329, produced a weaker association (9.6 10 3) that
was a result of modest LD with this associated variant but
conferred no independent effects. None of the FTO obesity-
associated markers were related to AIWG in our sample
(Table 2). SeveralMC4R variants showed a trend association,
but none met significance after correction for multiple
comparisons (adjusted significance threshold for 19 markers
Po0.003). The single nonsynonymous variant in FAAH did
not achieve significance in our data set.
Figure 1 Gene variants predict weight gain across 8 weeks of risperidone treatment. (a) A greater risk for weight gain is conferred by T-allele dosage at cannabinoid
receptor (CNR1) rs806378 (P¼ 1.0 10 6). (b) The G-allele of leptin (LEP) rs7799039 acts dominantly to increase risk for antipsychotic-induced weight gain
(P¼ 1.4 10 4), whereas AA homozygotes are relatively protected.
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Although weight gain was not correlated with risperidone
dose (r¼  0.09, P¼ 0.24), we repeated the analyses using
dose as a covariate to rule out any confounding effects;
risperidone dose did not contribute to the effects of genotype
(rs806378, P¼ 0.68; rs1049353, P¼ 0.68; rs7799039,
P¼ 0.86). In addition, as trough plasma levels were obtained
for the RUPP samples, the markers with significant associa-
tions were analyzed in the RUPP subsample using plasma
level as a covariate. Surprisingly, despite the much smaller
sample size (n¼ 34), rs1049353 (Po0.005) and rs7799039
(Po0.05) both retained nominal significance, however,
rs806378 did not (P¼ 0.26); plasma level did not account for
these effects (rs806378, P¼ 0.41; rs1049353, P¼ 0.49;
rs7799039, P¼ 0.54). Finally, although there were no
significant difference in weight gained (Z-score) in the
Caucasian versus non-Caucasian groups, analyses of the
three significant markers included ethnicity as a covariate and
were reanalyzed in the Caucasian subsample (n¼ 119). No
main effect of ethnicity was observed (rs806378 P¼ 0.60,
rs1049353 P¼ 0.66, rs7799039 P¼ 0.86), P-values were
similar whether or not ethnicity was included in the model, and
all three SNPs retained significance in the smaller Caucasian
subsample (rs806378, P¼ 1.8 10 3; rs1049353, P¼ 8.63
 10 6; rs7799039, P¼ 4.5 10 5).
In order to test for overlapping or interactive effects between
these three variants, we calculated a risk score for each
subject by assigning one point for the presence of a risk allele
at each identified locus (Figure 2). This model strongly
predicted weight gain in both the overall sample (P¼ 1.29
 10 9) and the Caucasian subset (P¼ 2.13 10 11).
The addition of each risk allele conferred an independent
risk; subjects with 0 or 1 risk alleles (combined as only one
subject had no risk alleles) gained the least weight and those
with three alleles gained the most (Cohen’s D effect size 0.46
for 0/1 versus 2 and 0.85 for 0/1 versus 3). In all, 64% of the
variance in weight gained was explained by the combined risk
by time model.
Discussion
Our results form strong support for individual genetic variation
in the LEP and CNR1 genes as moderators of AIWG. SGAs
may impact appetite, weight gain and energy expenditure
through direct or indirect interactions with these key regulators
of energy balance. Although the exact mechanisms of these
effects are unknown, our data suggest that genetic regulation
of energy balance components may impact energy home-
ostasis in the face of antipsychotic exposure. The prominent
role of promoter, rather than coding, variants in both genes
implies that regulation of gene expression may be an
important mechanism. Future studies should examine gene
expression profiles during SGA exposure, with particular
interest in the expression of the significantly associated loci
identified in this report.
In this sample of children and adolescents with ASD,
individuals with at least one copy of the T-allele of CNR1 SNP
rs806378 showed greater weight gain during low-dose
risperidone exposure, evident even after only the first 8
weeks of treatment. As our data are in agreement with a prior
study in adults with schizophrenia receiving olanzapine,44 this
variant may confer broad risk for AIWG. This SNP localizes
immediately adjacent to the coding region in either the
putative promoter, the 50 untranslated region or the large first
intron in alternative transcripts ofCNR1, and mechanistically it
has been suggested to impact a binding site for a transcription
factor involved in regulating hypothalamic feeding drives.44
Despite the inclusion of the upstream alternative promoter
and untranslated exon in several prior studies, all association
signals have localized to the 30 LD block tagged in the present
analyses. Allelic heterogeneity and possible differential ethnic
risk affecting this locus may help to explain disparate findings
in published studies. Another nearby SNP (rs806377) and a 30
untranslated region polymorphism (rs806368) previously
reported to associate with obesity phenotypes were not
associated with AIWG in our sample.37,60 Association with
fat mass and BMI of the G-allele of synonymous SNP
rs1049353 was previously reported and replicated,61,62
although not all studies are in agreement.60,63,64 In all positive
reports, including the present study, the G-allele is associated
with risk for weight gain or related phenotypes. Synonymous
SNPs may be directly relevant by altering translational
efficiency or by impacting mRNA processing, stability or
localization, or may reflect indirect association through
LD with a nearby functional variant. Indeed, HaploReg
analysis indicates that this SNP is in near perfect LD with a
30 untranslated region variant mapping to a region of active
transcription factor binding (rs4707436). The two associated
CNR1 variants reflect independent associations, as LD
between these two SNPs is negligible (r2¼ 0.01). Despite
previous support,45 the single nonsynonymous variant in
FAAH was non-significant in our data set.
Figure 2 Amount of weight gain is moderated by risk allele load. A risk score
(0–3) was assigned to each subject corresponding to the number of loci with risk
alleles present for each significant marker (leptin rs7799039 and cannabinoid
receptor 1 rs806378 and rs1049353). Risk allele dosage predicted amount of weight
gain (P¼ 1.29 10 9, Cohen’s D effect size¼ 0.85). Only one subject had no risk
alleles and was therefore included in the 1-allele group.
Energy balance genes and risperidone weight gain
EL Nurmi et al
5
Translational Psychiatry
We report a substantial contribution of the LEP rs7799039
(G-2548A) promoter SNP with individual differences in weight
gain, as have multiple prior studies, including one in
children.40 In our sample, the G-allele conferred a dominant
effect on risk for weight gain. Data from several groups
support this directionality of effect for AIWG65–69 and related
phenotypes.70,71 A few studies have found no evidence for
association at this locus.72,73 Three studies have found
association of the A-allele with AIWG in Asian popula-
tions,74–76 as well as a single smaller mixed-ethnicity pediatric
study, which also showed LEP elevation for carriers of the
A-allele.40 Taken together, our data stand in agreement with
the majority of reports; those studies with contrary patterns of
association with AIWG and the A-allele appear to differ by
virtue of effects of ethnicity. Of the two negative reports, one
sample was significantly smaller than ours, and both involved
a mixture of various antipsychotics, including other concomi-
tant medications. It is conceivable that some associations with
AIWG will emerge to be medication specific. Interestingly, in
the only prior pediatric report, A-carriers had greater weight
gain and higher LEP concentrations at lower BMIs overall,
however, the magnitude of the increase in LEP with BMI was
greater for GG homozygotes, arguing that this SNP may
indeed produce differential LEP expression.40 In concordance
with this finding, higher transcription factor binding to the LEP
promoter, LEP expression and LEP secretion has been
demonstrated in non-obese AA homozygotes compared with
G-carriers.77 Interestingly, in silico investigation also suggests
that this SNP may be functional, as it tags an LD block
annotated by HaploReg as containing multiple enhancer
elements.
The marginal association of SNPs in the obesity-related
gene, MC4R deserves mention. Our MC4R results stand in
contrast to recent strong associations with AIWG. However,
we note three possibly relevant study differences. Our sample
tested only associations with risperidone monotherapy,
whereas the positive MC4R reports examined associations
with multiple, mostly other SGAs, not risperidone. Our sample
is considerably younger (mean age 9 years) than most; it is
conceivable that age and developmental stage interacts with
gene–weight gain relations. Our sample is also unique in that
is only includes subjects with ASD, rather than the majority of
reports of adolescents and adults with psychotic and other
disorders. Each of these differences may be relevant to
genetic associations with AIWG. Clinically, it is of note that the
inverse correlation of AIWG with clinical improvement on the
primary outcome measure concurs with our RUPP report that
weight gained negatively mediated risperidone benefit,78
which could have implications for drug development. However,
the mechanism of antipsychotic action in autism-associated
aggression may be distinct from activity in psychotic disorders;
indeed, the relationship between efficacy and weight gain
appears to be positively correlated in studies of psychosis.79,80
Our investigation likely benefited from several features: the
largely treatment-naive sample of youth with a single disorder
(ASD), observations of weight with risperidone monotherapy
only, weekly monitoring and data collection allowing a
powerful repeated measures statistical model and a more
rigorous query of candidate genes. As repeated measures
of weight gain across eight visits were tightly correlated
(r¼ 0.95), this study was powered to detect effect sizes
ranging from 0.15 to 0.32 based on the minor allele frequency
of the variant. The clinical impact of the variants reported here
appear significant given the large effect size. It is conceivable
that these associations could become even more robust if
measured over longer periods of drug exposure. To our
knowledge, this study represents the only examination of the
endocannabinoid system in children, who may suffer greater
morbidity both in terms of magnitude of weight gained and
health impact across the lifespan. Importantly, the support for
involvement of CNR1 signaling suggests that the use of
known drug modulators of this system, such as those similar
to rimonabant, could limit the extent of AIWG, especially in
those individuals at higher genetic risk.
Although our study is limited by a relatively modest number
of subjects, results did withstand correction for multiple
testing. Although a functional variant in the FAAH enzyme
and highly associated FTO markers were chosen for inclusion
based on prior data, these genes were not comprehensively
screened. A larger sample would provide the statistical power
to permit the inclusion of additional markers, either within
these genes or other components of the energy balance
system, or allow a full selection-unbiased genome-wide
association study. Similarly, other metabolic response ‘phe-
notypes’, such as hip and waist circumference, lipid profile
and measures of glucose metabolism, could also be
examined,6 although the current sample size lacks desired
power for broader exploration.
Taken together, our data and prior evidence support a
moderating role of genetic variation in the LEP and endo-
cannabinoid system on AIWG. Additional efforts to replicate
and extend these findings to larger samples, to understand
the biological basis for these associations and to examine
possible clinical implications by a priori risk prediction and
genotype-driven treatment matching are suggested as future
directions. Polygenic inheritance, small effect sizes and
genetic and phenotypic heterogeneity have limited the
identification of genetic moderators of complex phenotypes.
However, understanding the risk for tractable and quantitative
adverse drug effects informed by underlying biology may pose
a less complex genetic question. The pharmacogenetics of
AIWG may offer a window into the intricate physiology of
energy balance and guide the personalization of treatment to
improve clinical outcomes.
Conflict of interest
Dr Aman has received consulting fees from Bristol-Myers Squibb,
BioMarin, Roche and Supernus. Dr Aman also reports research
support from Bristol-Myers Squibb and Johnson and Johnson.
Dr Arnold has received research funding from Curemark, Shire and
Lilly, and has consulted on advisory boards for AstraZeneca,
Biomarin, Novartis, Noven, Seaside Therapeutics and Shire.
Dr Handen reports research support from Eli Lilly, Curemark and
Bristol Myers Squibb. Dr McCracken reports receiving consulting fees
from BioMarin, Novartis and PharmaNet; he also reports research
support from Bristol-Myers Squibb, Roche and Seaside Therapeutics.
Dr McDougle reports having received consultant fees from Bristol-
Myers Squibb, Hoffman-LaRoche and Forest Research Institute; he
has also received research support and is on the speakers’ bureau of
Bristol-Myers Squibb. Dr Scahill reports receiving consultant fees
Energy balance genes and risperidone weight gain
EL Nurmi et al
6
Translational Psychiatry
from Brackett, Pfizer, Hoffman, BioMarin; he has also received
research support from Pfizer, Shire and Hoffman. Dr Stigler reports
receiving research support from Bristol-Myers Squibb, Eli Lilly,
Jansen, Novartis, Forest Research Institute and Seaside
Therapeutics. The remaining authors declare no conflict of interest.
Acknowledgements. This work was partially supported by the following
sources: NIMH grants T32MH073517 (ELN), K23 MH094613 (ELN), K24
MH010805 (JTM) and N01MH70010 (JTM), N01MH80011 and U10MH66768
(MGA), N01MH70001 and U10MH66766 (CJM), N01MH70009 and U10MH66764
(LLS) and a grant from the Korczak Foundation (LLS). Study medications were
donated by Janssen Pharmaceutica.
1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al.
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry
1999; 156: 1686–1696.
2. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg
JC et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib
pairs. Psychiatr Genet 2005; 15: 285–289.
3. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-
binding profiles. Mol Psychiatry 2008; 13: 27–35.
4. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene
and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol
2007; 10: 697–704.
5. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ. Pharmacogenetics
of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2011;
17: 242–266.
6. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P et al. Genomewide
pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry
2011; 16: 321–332.
7. Albarado DC, McClaine J, Stephens JM, Mynatt RL, Ye J, Bannon AW et al. Impaired
coordination of nutrient intake and substrate oxidation in melanocortin-4 receptor knockout
mice. Endocrinology 2004; 145: 243–252.
8. Song CK, Jackson RM, Harris RB, Richard D, Bartness TJ. Melanocortin-4 receptor mRNA
is expressed in sympathetic nervous system outflow neurons to white adipose tissue.
Am J Physiol Regul Integr Comp Physiol 2005; 289: R1467–R1476.
9. Farooqi IS, O’Rahilly S. Genetic factors in human obesity. Obes Rev 2007; 8(Suppl 1):
37–40.
10. Fredriksson R, Hagglund M, Olszewski PK, Stephansson O, Jacobsson JA, Olszewska AM
et al. The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and
expressed in neurons of feeding-related nuclei of the brain. Endocrinology 2008; 149:
2062–2071.
11. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM et al. A
common variant in the FTO gene is associated with body mass index and predisposes to
childhood and adult obesity. Science 2007; 316: 889–894.
12. Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity risk: a
meta-analysis. BMC Med 2011; 9: 71.
13. Tung YC, Ayuso E, Shan X, Bosch F, O’Rahilly S, Coll AP et al. Hypothalamic-specific
manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in
rats. PLoS One 2010; 5: e8771.
14. Tung YC, Yeo GS. From GWAS to biology: lessons from FTO. Ann N Y Acad Sci 2011;
1220: 162–171.
15. Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL et al. Leptin
activates anorexigenic POMC neurons through a neural network in the arcuate nucleus.
Nature 2001; 411: 480–484.
16. Opland DM, Leinninger GM, Myers MG Jr.. Modulation of the mesolimbic dopamine system
by leptin. Brain Res 2010; 1350: 65–70.
17. Davis JF, Choi DL, Schurdak JD, Fitzgerald MF, Clegg DJ, Lipton JW et al. Leptin regulates
energy balance and motivation through action at distinct neural circuits. Biol Psychiatry
2011; 69: 668–674.
18. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, Boss O, Pernin A, Chin WW et al. Direct
effects of leptin on brown and white adipose tissue. J Clin Invest 1997; 100: 2858–2864.
19. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of
glucose metabolism in mice by leptin treatment. Nature 1997; 389: 374–377.
20. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of
the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.
21. Matheny M, Zhang Y, Shapiro A, Tumer N, Scarpace PJ. Central overexpression of leptin
antagonist reduces wheel running and underscores importance of endogenous leptin
receptor activity in energy homeostasis. Am J Physiol Regul Integr Comp Physiol 2009;
297: R1254–R1261.
22. Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obes Rev 2011;
12: e315–e323.
23. Yu Z, Han S, Cao X, Zhu C, Wang X, Guo X. Genetic polymorphisms in adipokine genes
and the risk of obesity: a systematic review and meta-analysis. Obesity (Silver Spring)
2011; 20: 396–406.
24. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the
endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;
27: 73–100.
25. Verty AN, McGregor IS, Mallet PE. The dopamine receptor antagonist SCH 23390
attenuates feeding induced by Delta9-tetrahydrocannabinol. Brain Res 2004; 1020:
188–195.
26. Duarte C, Alonso R, Bichet N, Cohen C, Soubrie P, Thiebot MH. Blockade by the
cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by
quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychophar-
macology 2004; 29: 911–920.
27. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P. Hypersensitization of the Orexin
1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1
antagonist, SR141716. J Biol Chem 2003; 278: 23731–23737.
28. Verty AN, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between
CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake.
Endocrinology 2004; 145: 3224–3231.
29. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist
SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004;
143: 520–523.
30. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al. Leptin-regulated
endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.
31. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance.
Nat Neurosci 2005; 8: 585–589.
32. Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism.
J Neuroendocrinol 2008; 20(Suppl 1): 124–129.
33. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of
CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism
(CP-55940). Behav Pharmacol 2005; 16: 381–388.
34. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug
Discov 2008; 7: 438–455.
35. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor
knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin
sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640–648.
36. Lieb W, Manning AK, Florez JC, Dupuis J, Cupples LA, McAteer JB et al. Variants in the
CNR1 and the FAAH genes and adiposity traits in the community. Obesity (Silver Spring)
2009; 17: 755–760.
37. Schleinitz D, Carmienke S, Bottcher Y, Tonjes A, Berndt J, Kloting N et al. Role of genetic
variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human
obesity. Pharmacogenomics 2010; 11: 693–702.
38. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a
cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or
obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:
761–775.
39. Sentissi O, Epelbaum J, Olie JP, Poirier MF. Leptin and ghrelin levels in patients with
schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008; 34:
1189–1199.
40. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA. Leptin gene -
2548G/A variants predict risperidone-associated weight gain in children and adolescents.
Psychiatr Genet 2009; 19: 320–327.
41. Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S et al. Genetic association
study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene.
Pharmacogenomics J 2013; 13: 272–279.
42. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT et al.
Association between common variants near the melanocortin 4 receptor gene
and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012; 69:
904–912.
43. Cheng MC, Liao DL, Hsiung CA, Chen CY, Liao YC, Chen CH. Chronic treatment
with aripiprazole induces differential gene expression in the rat frontal cortex.
Int J Neuropsychopharmacol 2008; 11: 207–216.
44. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP et al. A common polymorphism
in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight
gain in Schizophrenia. Neuropsychopharmacology 2010; 35: 1315–1324.
45. Monteleone P, Milano W, Petrella C, Canestrelli B, Maj M. Endocannabinoid Pro129Thr
FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with
antipsychotic-induced weight gain. J Clin Psychopharmacol 2010; 30: 441–445.
46. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G et al. Weight gain
associated with olanzapine and risperidone in adolescent patients: a comparative
prospective study. J Am Acad Child Adolesc Psychiatry 2002; 41: 337–343.
47. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated
with risperidone and conventional antipsychotics over six months. J Child Adolesc
Psychopharmacol 1998; 8: 151–159.
48. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L et al. Risperidone-
associated weight gain in children and adolescents: a retrospective chart review. J Child
Adolesc Psychopharmacol 2000; 10: 259–268.
Energy balance genes and risperidone weight gain
EL Nurmi et al
7
Translational Psychiatry
49. Woods SW, Martin A, Spector SG, McGlashan TH. Effects of development on olanzapine-
associated adverse events. J Am Acad Child Adolesc Psychiatry 2002; 41: 1439–1446.
50. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J et al. Weight and
leptin changes among risperidone-treated youths with autism: 6-month prospective data.
Am J Psychiatry 2004; 161: 1125–1127.
51. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al. Risperidone in
children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314–321.
52. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C et al. Medication and
parent training in children with pervasive developmental disorders and serious behavior
problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry
2009; 48: 1143–1154.
53. Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone
and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients:
simultaneous determination by a high performance liquid chromatography with
electrochemical detection. Pharmacopsychiatry 1998; 31: 102–109.
54. Growth Chart Training: Resources: SAS Program. http://www.cdc.gov/nccdphp/dnpao/
growthcharts/resources/sas.htm 2011 Accessed Date 2011.
55. deBakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in
genetic association studies. Nat Genet 2005; 37: 1217–1223.
56. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web
site. Genome Res 2005; 15: 1592–1593.
57. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al. The human
genome browser at UCSC. Genome Res 2002; 12: 996–1006.
58. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ et al. ENCODE
whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res 2012;
40, Database issue D912–D917.
59. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and
regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res
2012; 40, Database issue D930–D934.
60. Jaeger JP, Mattevi VS, Callegari-Jacques SM, Hutz MH. Cannabinoid type-1 receptor
gene polymorphisms are associated with central obesity in a Southern Brazilian population.
Dis Markers 2008; 25: 67–74.
61. Luis DA, Gonzalez Sagrado M, Aller R, Izaola O, Conde R, Perez Castrillon JL et al.
[G1359A polymorphism of the cannabinoid receptor gene (CNR1) on anthropometric
parameters and cardiovascular risk factors in patients with morbid obesity]. Nutr Hosp
2009; 24: 688–692.
62. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C et al.
Association between cannabinoid type-1 receptor polymorphism and body mass index in a
southern Italian population. Int J Obes (Lond) 2007; 31: 908–912.
63. de Luis DA, Gonzalez Sagrado M, Aller R, Izaola O, Conde R, Romero E. G1359A
polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients
with diabetes mellitus type 2. Nutr Hosp 2010; 25: 34–38.
64. Park YM, Choi JE, Kang SG, Koo SH, Kim L, Geum D et al. Cannabinoid type 1 receptor
gene polymorphisms are not associated with olanzapine-induced weight gain. Hum
Psychopharmacol 2011; 26: 332–337.
65. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor
and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian
subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195–200.
66. Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller DD. Leptin and leptin receptor gene
polymorphisms and increases in body mass index (BMI) from olanzapine treatment in
persons with schizophrenia. Psychopharmacol Bull 2007; 40: 57–62.
67. Kang SG, Lee HJ, Park YM, Choi JE, Han C, Kim YK et al. Possible association between
the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog
Neuropsychopharmacol Biol Psychiatry 2008; 32: 160–163.
68. Yevtushenko OO, Cooper SJ, O’Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence
of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on
metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008; 192: 424–428.
69. Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Buttner S et al. Association
study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body
weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38: 134–141.
70. Fernandez E, Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D et al. Polymorphisms
of the LEP- and LEPR genes, metabolic profile after prolonged clozapine administration
and response to the antidiabetic metformin. Schizophr Res 2010; 121: 213–217.
71. Kuo PH, Kao CF, Chen PY, Chen CH, Tsai YS, Lu ML et al. Polymorphisms of INSIG2,
MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic
patients. J Clin Psychopharmacol 2011; 31: 705–711.
72. Opgen-Rhein C, Brandl EJ, Muller DJ, Neuhaus AH, Tiwari AK, Sander T et al. Association
of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a
German sample. Pharmacogenomics 2010; 11: 773–780.
73. Perez-Iglesias R, Mata I, Amado JA, Berja A, Garcia-Unzueta MT, Martinez Garcia O et al.
Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with
antipsychotic treatment. J Clin Psychopharmacol 2010; 30: 661–666.
74. Zhang ZJ, Yao ZJ, Mou XD, Chen JF, Zhu RX, Liu W et al. [Association of -2548G/A
functional polymorphism in the promoter region of leptin gene with antipsychotic agent-
induced weight gain]. Zhonghua Yi Xue Za Zhi 2003; 83: 2119–2123.
75. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q et al. Association of clozapine-
induced weight gain with a polymorphism in the leptin promoter region in patients with
chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007; 27:
246–251.
76. Wu R, Zhao J, Shao P, Ou J, Chang M. Genetic predictors of antipsychotic-induced weight
gain: a case-matched multi-gene study. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011; 36:
720–723.
77. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter
region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm
Metab Res 2002; 34: 355–359.
78. Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S et al. Moderators,
mediators, and other predictors of risperidone response in children with autistic disorder
and irritability. J Child Adolesc Psychopharmacol 2010; 20: 83–93.
79. Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD. Weight gain as a prognostic
indicator of therapeutic improvement during acute treatment of schizophrenia with placebo
or active antipsychotic. J Psychopharmacol 2005; 19(6 Suppl): 110–117.
80. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D et al. The association between
weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res
2011; 128: 166–170.
81. Xi B, Wang C, Wang R, Huang Y. FTO gene polymorphisms are associated with obesity
and type 2 diabetes in East Asian populations: an update. Obesity (Silver Spring) 2011; 19:
236–237; author reply 238.
82. Li S, Zhao JH, Luan J, Luben RN, Rodwell SA, Khaw KT et al. Cumulative effects and
predictive value of common obesity-susceptibility variants identified by genome-wide
association studies. Am J Clin Nutr 2010; 91: 184–190.
83. Scott RA, Bailey ME, Moran CN, Wilson RH, Fuku N, Tanaka M et al. FTO genotype and
adiposity in children: physical activity levels influence the effect of the risk genotype in
adolescent males. Eur J Hum Genet 2010; 18: 1339–1343.
84. Beckers S, Zegers D, de Freitas F, Mertens IL, Van Gaal LF, Van Hul W. Association study
of MC4R with complex obesity and replication of the rs17782313 association signal. Mol
Genet Metab 2011; 103: 71–75.
85. Malhotra AK, Correll CU, Chowdhury NI, Mu¨ller DJ, Gregersen PK, Lee AT et al. Common
variants near the melanocortin 4 receptor gene are associated with severe antipsychotic
drug-induced weight gain. Arch Gen Psychiatry 2012; 69: 904–912.
86. Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC,
Heerdink ER. Association between LEP and LEPR gene polymorphisms and
dyslipidemia in patients using atypical antipsychotic medication. Psychiatr Genet 2010;
20: 311–316.
87. Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER.
Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients
using antipsychotic medication in a naturalistic setting. Pharmacogenomics 2011; 12:
919–923.
88. Labayen I, Ruiz JR, Moreno LA, Ortega FB, Beghin L, DeHenauw S et al. The
effect of ponderal index at birth on the relationships between common LEP and
LEPR polymorphisms and adiposity in adolescents. Obesity (Silver Spring) 2011; 19:
2038–2045.
89. Erez G, Tirosh A, Rudich A, Meiner V, Schwarzfuchs D, Sharon N et al. Phenotypic and
genetic variation in leptin as determinants of weight regain. Int J Obes (Lond) 2011; 35:
785–792.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
ShareAlike 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Energy balance genes and risperidone weight gain
EL Nurmi et al
8
Translational Psychiatry
